Organization
Oregon Health and Science U, Portland, United States of america
1 abstract
Abstract
ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF GUSELKUMAB IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIALOrg: Oregon Health and Science U, Portland, United States of america, Guy’s and St. Thomas NHS Foundation Trust, London, United Kingdom, Memorial University of Newfoundland, St. John’s, Canada, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, Icahn School of Medicine at Mt Sinai, Dermatology, New York, United States of america,